Serum Uric Acid Reduction Following Use of Canssu5®, a Standardized Orthosiphon stamineus Extract, in Adults with Hyperuricemia: A Retrospective Case Study
Integrative Biomedical Research · 01.04.2026 · 10 (1) · 1-11
DOI: 10.25163/biomedical.10110722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrative Biomedical Research, online erschienen am 01.04.2026.
Abstract (Originalsprache)
Background
Hyperuricemia remains a central biochemical driver of gout and is increasingly implicated in broader cardiometabolic and renal disorders. Although pharmacologic urate-lowering therapies are effective, their use is sometimes constrained by intolerance, adherence challenges, or patient preference for alternative approaches. In this context, botanically derived compounds with multi-target activity have begun to attract interest, though clinical evidence remains limited.
Methods
This retrospective case series evaluated ten adults with laboratory-confirmed hyperuricemia who consumed Canssu5®, a standardized Orthosiphon stamineus extract, under real-world conditions. Serum uric acid (SUA) values obtained from accredited laboratories before and after supplementation were analyzed using paired-sample statistical methods. Individual-level responses, percentage reductions, and achievement of clinically relevant SUA thresholds were examined descriptively.
Results
All participants demonstrated reductions in SUA following product use (Table 1; Figure 1). Mean SUA declined from 0.592 ± 0.091 mmol/L to 0.364 ± 0.059 mmol/L, corresponding to a mean reduction of 0.228 mmol/L (37.4%). The change was statistically significant (t(9) = 7.78, p < 0.001), with a large effect size (Cohen’s d ≈ 2.46). Seventy percent of participants achieved post-treatment SUA levels below 0.40 mmol/L. No adverse events were reported.
Conclusion
Use of a standardized Orthosiphon stamineus extract was associated with consistent reductions in serum uric acid across all cases. While the findings are encouraging, the retrospective design and small sample size limit causal interpretation. These observations should be considered preliminary and warrant confirmation in controlled clinical trials.
Zitieren
APA
(2026). Serum Uric Acid Reduction Following Use of Canssu5®, a Standardized Orthosiphon stamineus Extract, in Adults with Hyperuricemia: A Retrospective Case Study. Integrative Biomedical Research, 10(1), 1-11. https://doi.org/10.25163/biomedical.10110722
Vancouver
Serum Uric Acid Reduction Following Use of Canssu5®, a Standardized Orthosiphon stamineus Extract, in Adults with Hyperuricemia: A Retrospective Case Study. Integrative Biomedical Research. 2026;10(1):1-11. doi:10.25163/biomedical.10110722
BibTeX
@article{euvimed2026,
title = {Serum Uric Acid Reduction Following Use of Canssu5®, a Standardized Orthosiphon stamineus Extract, in Adults with Hyperuricemia: A Retrospective Case Study},
journal = {Integrative Biomedical Research},
year = {2026},
volume = {10},
number = {1},
pages = {1--11},
doi = {10.25163/biomedical.10110722}
}
EUVIMED